Crinetics Pharmaceuticals Inc diskutieren
Crinetics Pharmaceuticals Inc
WKN: A2JQTJ / Symbol: CRNX / Name: Crinetics Pharmaceuticals / Aktie / Small Cap /
47,20 €
-1,65 %
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $54.00 to $55.00. They now have an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Piper Sandler from $56.00 to $97.00. They now have an "overweight" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Morgan Stanley from $50.00 to $70.00. They now have an "overweight" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Robert W. Baird from $52.00 to $62.00. They now have an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $55.00 to $74.00. They now have an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $97.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at JPMorgan Chase & Co. from $47.00 to $54.00. They now have an "overweight" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $73.00 price target on the stock, down previously from $74.00.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at HC Wainwright from $60.00 to $69.00. They now have a "buy" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $90.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Neueste Beiträge
Barclays_PLC in Varonis Systems Inc. diskutieren